Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/1/23 → 8/31/24

Funding

  • Dana-Farber Cancer Institute (1331805 // 3U01CA233169-05S1)
  • National Cancer Institute (1331805 // 3U01CA233169-05S1)